Clinical Trial Update: Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating disitamab vedotin with tislelizumab in advanced HER2-positive colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Colorectal Neoplasms | Phase 2 | Status: UNKNOWN